{
  "docId": "019de073-948a-7043-8b3b-a5ac9bb504f9",
  "docSlug": "d72f38beef66cb68e946399178678a94",
  "documentTitle": "Roivant Sciences | Investor Presentation Deck | 21 slides",
  "authorId": "roivant-sciences",
  "authorName": "Immunovant",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 21,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "why_now",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-948a-7043-8b3b-a5ac9bb504f9/6",
  "deckHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9",
  "deckJsonHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9.json",
  "deckAnchorHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Some patient populations and indications likely need maximal IgG suppression (up to ~80%) to maximize clinical benefit and duration of this need will vary",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "837ca758-5936-4cfe-948b-2fdb52f90632",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "IgG reduction is a well-established biomarker for degree of clinical response",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9af6c966-c69d-4b04-afdd-05e13365b13b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "We believe broad validity of IgG as a biomarker across indications enables an accelerated development path for a new anti-FcRn particularly with proprietary patient level data on file",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a53a3918-54fd-4dd4-af84-f82150258ec7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.28,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Source: Anti-FcRn data publicly disclosed by Immunovant, Argenx, UCB, and Momenta",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78ab4a11-a086-4a4b-a364-6a5cad786d48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Anti-FcRn market is unique in terms of breadth of potential indications and in terms of having a strong biomarker",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d4c33e5-2673-4a72-b215-efda790ed2ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a1554744-0a52-4a46-b2b1-7db0b7f578b5",
      "evidence": "The slide mentions 'patient populations and indications', indicating that the audience is patients or medical professionals.",
      "confidence": 0.7
    },
    {
      "name": "Core Message Extraction",
      "slug": "core-message-extraction",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "32613a6e-782c-4c6a-a8f9-db7c9e07df16",
      "evidence": "The slide clearly states the core message: 'Anti-FcRn market is unique in terms of breadth of potential indications and in terms of having a strong biomarker'.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}